iBio, Inc., Newark, disclosed that a patent to increase influenza vaccine performance through the use of iBio’s proprietary iBioModulator fusion protein technology has been allowed in China. The patent will further broaden the territories in which patent exclusivity has been secured for this technology. The patent was also issued in the U.S.
“China, by virtue of the scale of its rapidly-emerging domestic market and need for new biopharmaceutical technology infrastructure to address influenza and other emerging infectious disease threats, is a target market for us,” said Robert Erwin, president of iBio. “This new intellectual property protection will further facilitate our ability to license our technology for the Chinese market.”
The vaccine industry is increasingly focused on the development of recombinant vaccines instead of live virus vaccines. By contast, lichenase protein, when fused to antigens through the use of the iBioModulator technology, can enhance duration of an immune response, improve production economies and increase product stability in comparison to conventional combinations, according to the company.
iBio uses an automated process to produce the vaccine materials that features robotics and other technology.
Previously published data demonstrated significant improvement in candidate vaccine efficacy in animal models when iBioModulator technology was employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus.
Comments are closed.